gilead post solid quarter total revenue vs non-gaap
ep vs beat consensu estim product sale guidanc
increas y/i think
under-valued cash flow though major re-rat like requir pipelin
program capabl drive revenu growth
world-wide hiv/hbv sale q/q y/i in-lin
consensu hcv sale q/q y/i
consensu note hiv hcv
revenu benefit account adjust prior period rebat letairi
revenu ahead launch gener somewhat
later anticip product sale q/q y/i ahead
differ due almost entir account adjust upsid
letairi total revenu q/q y/i ahead consensu
estim gilead report non-gaap gross margin vs
non-gaap sg expens revenu
revenu vs respect gilead report tax rate
vs non-gaap ep q/q y/i consensu
gilead increas product sale guidanc
y/i reiter guidanc gross margin non-gaap expens non-
sg expens non- effect tax rate adjust estim
reflect recent trend updat guidanc product revenu estim
increas non-gaap ep estim
hiv/hbv sale q/q y/i line consensu
though gilead busi estim q/q
y/i vs demand trend remain strong prescript
y/i biktarvi gener q/q revenu fifth full quarter
market biktarvi number one prescrib regimen treatment-na
switch patient new patient start biktarvi growth
biktarvi scrip q/q off-set declin prescript gilead hiv regimen
total hiv scrip q/q gilead report taf-bas regimen
account gilead hiv prescript volum
hiv sale eu q/q y/i benefit due
adjust statutori revenu clawback reserv sale would declin
sequenti absent adjust sale continu impact
avail truvada gener sever european countri gilead note
rate declin moder due launch descovy-bas regimen across europ
biktarvi approv eu june number one prescrib regimen
germani franc spain biktarvi launch itali june juli
avail european market gilead expect launch biktarvi
across europ help off-set impact gener possibl return growth
pleas see page report import disclosur
gilead market leader treatment hiv hcv acquir car-t oncolog
platform kite expect combin launch new taf-bas
combin pill hiv market growth share gain price increas hiv franchis
sale grow compound-annual-growth-rate despit viread patent expir
expect declin gilead hcv franchis moder price patient volum begin
plateau project gilead hcv franchis gener world-wide sale
car-t therapi yescarta adopt standard care r/r dlbcl project
sale base dcf analysi gilead stock under-valued
expect cash flow
data phase ii studi nrti
data phase ii studi
cle sjogren syndrom
file fda ema approv
filgotinib ra
hcv sale
hiv franchis grow
despit expir
rest pipelin product
exce project
launch taf-bas pill allow
hiv franchis grow
expir tenofovir patent
candid pipelin
hcv sale fail achiev forecast
hiv franchis fail meet
project due competit major
chang treatment paradigm
gilead pipelin busi
develop effort fail produc
product capabl drive meaning
revenu earn
gilead develop market treatment hiv hbv hcv inflamm oncolog
gilead antivir portfolio biggest revenu driver gilead lead hiv franchis
anchor tenofovir well-toler efficaci nucleotid analog gilead
stribild genvoya odefsey descovi biktarvi togeth captur share
treatment-na hiv patient drive hiv franchis revenu project
revenu hcv franchis led sofosbuvir nucleosid inhibitor
result phase trial sofosbuvir-bas regimen shown potent
well toler high barrier viral resist expect hcv franchis
maintain approx revenu
 hcv revenu q/q y/i declin gilead note
mostli due larg state depart correct order receiv
iqvia-report prescript increas q/q ex-u hcv revenu
q/q y/i increas sequenti due benefit
adjust statutori revenu clawback reserv europ global hcv revenu
q/q y/i manag remain hope stabl
predict busi go forward slow steadi declin hcv market patient
start gilead subsidiari offer author gener epclusa
harvoni gilead note revenu asegua hcv gener made
hcv revenu quarter gilead expect gener reduc patient cost
expand access enabl gilead grow market share medicaid market
gilead record q/q y/i revenu yescarta sixth full quarter
market consensu estim
cancer center author treat patient across europ
effort remain identif appropri patient educ provid
yescarta clinic profil gilead continu work improv medicar
reimburs access patient year age
yescarta approv eu august gilead continu add certifi site
europ obtain reimburs germani franc spain gilead
record intern sale yescarta anticip european
approv yescarta gilead previous leas manufactur facil netherland
come on-lin yescarta revenu gilead
previous guid increment impli nearli doubl
revenu compar q/q growth launch continu
ramp yescarta expand european market base yescarta trend
increas yescarta estim
clinic trial yescarta continu pivot phase studi line dlbcl
phase ii studi combin atezolizumab initi
expect complet enrol data
anticip gilead also initi phase studi yescarta combin
utomilumab data phase ii studi line high-risk dlbcl
complet enrol pivot phase ii yescarta r/r indol
nhl complet enrol result anticip
addit gilead expect share data phase ii pivot studi formerli
construct yescarta differ manufactur mcl
complet enrol pivot phase ii adult
phase studi cll expect produc data
gilead expect begin clinic develop allogen car-t therapi
gilead recent initi phase i/ii studi tcr cell
therapi target r/r hpv solid tumor
expand research develop collabor bind glpg even
filgotinib phase finch program rheumatoid arthriti demonstr competit
efficaci profil potenti best-in-class safeti profil among jak inhibitor ra
earlier month gilead partner galapago announc follow pre-nda
meet fda gilead intend move forward nda submiss
filgotinib treatment rheumatoid arthriti ra year also anticip file
eu japan phase studi filgotinib on-going ulcer
coliti crohn diseas phase ii trial sever
inflammatori diseas also on-going
earlier juli galapago gilead enter expand collabor
effort align pipelin research effort compani deal
term includ up-front payment equiti invest galapago
gilead well royalti ex -filgotinib gilead sale product
exchang gilead receiv option right galapago current futur clinic
program outsid europ deal includ addit mileston payment specif
relat program compound galapago
fund discoveri develop effort complet qualifi ph ii studi
point gilead would option acquir expand licens fee
futur develop cost would share compound licens gilead
ex-filgotinib galapago would receiv royalti net sale gilead maintain
option right galapago program term collabor
addit three year thereaft program enter clinic
develop prior end collabor term compani also modifi
exist agreement surround filgotinib increas galapago commerci role
share develop cost
gilead perspect collabor help fortifi pipelin galapago
proven research engin pipelin novel candid larg market gilead
rel weak pipelin meager prospect revenu growth project
current portfolio produc revenu compound-annual-growth-rate period key
overhang stock project revenu growth increas low doubl
digit high suspect stock would re-rat
galapago toledo program fulli de-risk support solid earli
data address market potenti larg success would clearli
investor wait gilead revenu stabil three year declin
gilead updat guidanc impli revenu growth suggest
overal gilead busi final plateau expect gilead hcv busi
continu contract becom rel minor part gilead top-lin
launch taf regimen gilead hiv franchis continu
bright spot anticip y/i growth appear capabl compens
hcv trend well loss exclus letairi ranexa though hiv
competit increas gilead leadership posit seem safe next sever year
therefor day precipit declin gilead revenu appear past
gilead continu under-valued project cash flow dcf-base price
target remain nonetheless hiv franchis also face patent expiri
next sever year gilead prospect long-term top-lin growth appear middl
fact project product sale compound-annual-growth-rate gilead recent expans
glpg collabor add new candid larg market pipelin step
right direct though risk candid remain none yet proven
like blockbust suspect major re-rat share requir better
visibl pipelin candid capabl drive meaning reacceler revenu
gilead develop market treatment hiv hbv hcv inflamm
cancer gilead antivir portfolio largest revenu driver next
sever year gilead lead hiv franchis anchor tenofovir well-
franchis gener revenu captur share patient newli
initi hiv therapi tenofovir disoproxil fumar viread lost patent
protect gilead develop second gener version tenofovir
alafenamid taf improv safeti extend patent protect
project sale gilead hiv franchis grow
launch new patent-protect combin pill biktarvi bic/f/taf
genvoya e/c/f/taf descovi f/taf odefsey e/r/taf taf
regimen extend commerci life franchis gilead hcv franchis built
around sofosbuvir nucleosid inhibitor whose potenc high barrier
resist made cornerston market-lead all-or hcv
combin sovaldi sofosbuvir launch decemb
eu januari approv gilead harvoni sofosbuvir
ledispavir octob brought first fda-approv interferon free regimen
genotyp hcv patient largest hcv popul hcv
franchis got fast start post revenu
unfortun best day gilead hcv franchis past
emerg competit gilead hcv franchis gener revenu
estim continu declin gilead recent expand
oncolog franchis acquisit kite gilead gain
yescarta car-t therapi anhl approv fda octob
well lead car-t platform cowen project yescarta achiev
revenu third line anhl gilead emerg inflamm
franchis led filgotinib potent select inhibitor filgotinib
produc impress result phase ii trial rheumatoid arthriti ra
crohn diseas three phase studi ra think filgotinib
revenu potenti ra alon anticip world-wide regulatori file
hope gilead trough earn final sight three
year rapid declin hcv revenu project non-gaap ep
ep grow compound-annual-growth-rate gilead current trade
forward pe project cash flow yield base
dcf analysi gilead stock under-valued expect cash flow
data phase ii studi nrti
initi phase studi selonsertib diabet kidney diseas
data phase ii cutan lupu erythematosu
data phase ii sjogren syndrom
initi phase ii combin studi yescarta rituximab lenalidomid
data pivot phase ii mcl
file fda ema approv filgotinib rheumatoid arthriti
potenti fda approv descovi snda hiv prep
data phase iib atla combin studi nash
data phase ii studi hbv
initi phase studi filgotinib psoriat arthriti
initi phase ii studi uc
complet enrol phase yescarta line dlbcl
complet enrol pivot phase ii adult
data phase phase i/ii studi cll
submit descovi prep
initi phase studi filgotinib ankylos spondyl
data pivot phase ii yescarta indol nhl
data phase i/ii combin studi yescarta atezolizumab
preliminari data phase combin studi yescarta utomilumab
complet enrol phase ii yescarta line high-risk dlbcl
complet enrol ph ia mage solid tumor
data filgotinib select phase studi uc
initi clinic studi allogen
complet enrol filgotinib divers phase studi crohn diseas
complet enrol phase cilofexor psc
data phase hbv
cowen compani
cowen compani
total hiv total hcv ranexa product contract comp in-process acquisit cost total sale asset interest net income/ loss incom loss attribut non-controlling net fa net income/ loss ex fa forma ep ex fa share cowen
cowen compani
total hiv total hcv ranexa duct contract incom loss attribut non-controlling fa income/ loss ex fa forma ep ex fa share cowen
statement flow mm
cowen compani
depreci amort stock comp tax benefit employe stock chang net work capit ex cash provid use oper purchas /sale/matur market capit issuanc note acquisit net cash cash provid use invest proce issuanc of/ repurchas common proce issuanc of/ repurchas payment cash provid financ exchang rate chang increas decreas cash cash cash equival begin cash equival end summari oper exclud non-recur item cowen
cowen compani
financi year growth growth growth ranexa contract tax asset utilizedtax ratetax payment debtapprox free year growth ratetermin valu termin valu balanc dilut share per fulli dilut valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
gilead develop commerci drug number indic includ hiv hcv
hbv influenza cancer pulmonari hypertens forecast sale product
difficult outlook could alter new safety/efficaci find emerg
competit alter medic treatment paradigm chang pricing/
reimburs environ gilead stock price could also impact chang
outlook key pipelin program evalu market potenti drug
yet approv particularli riski moreov market exclus
gilead franchis depend patent subject challeng gener
drugmak valu gilead franchis could diminish lose
protect key patent
